<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40923937</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-7056</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Current opinion in gastroenterology</Title><ISOAbbreviation>Curr Opin Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Potassium-competitive acid blockers.</ArticleTitle><Pagination><StartPage>389</StartPage><EndPage>398</EndPage><MedlinePgn>389-398</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MOG.0000000000001127</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Acid suppression is the mainstay of management of common foregut disorders, including gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori infection. Drawbacks of standard management with proton pump inhibitors (PPIs) include acid lability requiring enteric coating, slow onset of effect, lack of suppression of nocturnal acid breakthrough, and need for administration before meals.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Potassium-competitive acid blockers (PCABs) are a novel class of acid suppressants that are effective in the management of symptomatic and erosive GERD, peptic ulcer disease and H. pylori infection. Administration before meals is not needed, and these agents achieve profound acid suppression right from the first dose, with control of daytime as well as nocturnal acid. In randomized controlled trials, PCABs are noninferior and often superior to PPIs, especially in healing of advanced grade esophagitis and eradication of treatment-naive as well as refractory H. pylori. The safety profile of PCABs over 10&#x200a;years of use is reassuring, although profound acid suppression may contribute to hypergastrinemia and increased risk of gastrointestinal infections.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">As PCABs become available in many countries around the globe, real-world use will allow further research to determine the clinical niche of these acid-suppressive agents.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Trevor A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Pediatrics.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gyawali</LastName><ForeName>C Prakash</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Washington University School of Medicine, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Gastroenterol</MedlineTA><NlmUniqueID>8506887</NlmUniqueID><ISSNLinking>0267-1379</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C552956">1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011758">Pyrroles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005764" MajorTopicYN="Y">Gastroesophageal Reflux</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016481" MajorTopicYN="Y">Helicobacter Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="Y">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010437" MajorTopicYN="Y">Peptic Ulcer</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016480" MajorTopicYN="N">Helicobacter pylori</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005744" MajorTopicYN="N">Gastric Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011758" MajorTopicYN="N" AutoHM="Y">Pyrroles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N" AutoHM="Y">Sulfonamides</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acid suppression</Keyword><Keyword MajorTopicYN="N">gastroesophageal reflux disease</Keyword><Keyword MajorTopicYN="N">peptic ulcer disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>10</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40923937</ArticleId><ArticleId IdType="doi">10.1097/MOG.0000000000001127</ArticleId><ArticleId IdType="pii">00001574-990000000-00212</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gyawali CP. Proton pump inhibitors in gastroesophageal reflux disease: friend or foe. Curr Gastroenterol Rep 2017; 19:46.</Citation></Reference><Reference><Citation>Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798&#x2013;1810.</Citation></Reference><Reference><Citation>Delshad SD, Almario CV, Chey WD, et al. Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms. Gastroenterology 2020; 158:1250.e2&#x2013;1261.e2.</Citation></Reference><Reference><Citation>Scarpignato C, Hunt RH. Editorial: potassium-competitive acid blockers for acid-related diseases-tegoprazan, a new kid on the block. Aliment Pharmacol Ther 2019; 50:960&#x2013;962.</Citation></Reference><Reference><Citation>Spechler SKJ, Dunbar K, et al. American Foregut Society White Paper Report on the use of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Foregut 2025. (in press).</Citation></Reference><Reference><Citation>Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005; 108:294&#x2013;307.</Citation></Reference><Reference><Citation>Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007; 5:1385&#x2013;1391.</Citation></Reference><Reference><Citation>Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008; 103:20&#x2013;26.</Citation></Reference><Reference><Citation>Scarpignato C, Hunt RH. Potassium-competitive acid blockers: current clinical use future developments. Curr Gastroenterol Rep 2024; 26:273&#x2013;293.</Citation></Reference><Reference><Citation>Garnock-Jones KP. Vonoprazan: first global approval. Drugs 2015; 75:439&#x2013;443.</Citation></Reference><Reference><Citation>Blair HA. Zastaprazan: first approval. Drugs 2024; 84:863&#x2013;866.</Citation></Reference><Reference><Citation>Engevik AC, Kaji I, Goldenring JR. The physiology of the Gastric Parietal Cell. Physiol Rev 2020; 100:573&#x2013;602.</Citation></Reference><Reference><Citation>Shin JM, Munson K, Vagin O, et al. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch 2009; 457:609&#x2013;622.</Citation></Reference><Reference><Citation>Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol 2015; 6:e94.</Citation></Reference><Reference><Citation>Otake K, Sakurai Y, Nishida H, et al. Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate (TAK-438). Adv Ther 2016; 33:1140&#x2013;1157.</Citation></Reference><Reference><Citation>Laine L, Sharma P, Mulford DJ, et al. Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects. Am J Gastroenterol 2022; 117:1158&#x2013;1161.</Citation></Reference><Reference><Citation>Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2022; 117:27&#x2013;56.</Citation></Reference><Reference><Citation>Scott DR, Munson KB, Marcus EA, et al. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Aliment Pharmacol Ther 2015; 42:1315&#x2013;1326.</Citation></Reference><Reference><Citation>Katz PO, Ginsberg GG, Hoyle PE, et al. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2007; 25:617&#x2013;628.</Citation></Reference><Reference><Citation>Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20&#x200a;mg compared with esomeprazole 20&#x200a;mg or rabeprazole 10&#x200a;mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther 2015; 42:719&#x2013;730.</Citation></Reference><Reference><Citation>Furuta T, Sugimoto M, Shirai N, Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics 2007; 8:1199&#x2013;1210.</Citation></Reference><Reference><Citation>Ichikawa H, Sugimoto M, Sugimoto K, et al. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol 2016; 31:716&#x2013;726.</Citation></Reference><Reference><Citation>Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 2016; 43:1048&#x2013;1059.</Citation></Reference><Reference><Citation>Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and proton pump inhibitor dosing. Clin Pharmacol Ther 2021; 109:1417&#x2013;1423.</Citation></Reference><Reference><Citation>Davis TA, Gyawali CP. Refractory gastroesophageal reflux disease: diagnosis and management. J Neurogastroenterol Motil 2024; 30:17&#x2013;28.</Citation></Reference><Reference><Citation>El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol 2018; 14:447&#x2013;460.</Citation></Reference><Reference><Citation>Lima JJ, Franciosi JP. Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs. Pharmacogenomics 2014; 15:</Citation></Reference><Reference><Citation>Tietto A, Faggin S, Scarpignato C, et al. Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Expert Opin Drug Metab Toxicol 2025; 21:53&#x2013;68.</Citation></Reference><Reference><Citation>Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther 2015; 42:685&#x2013;695.</Citation></Reference><Reference><Citation>Chen S, Liu D, Chen H, et al. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study. Aliment Pharmacol Ther 2022; 55:1524&#x2013;1533.</Citation></Reference><Reference><Citation>Laine L, DeVault K, Katz P, et al. Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology 2023; 164:61&#x2013;71.</Citation></Reference><Reference><Citation>Lee KJ, Son BK, Kim GH, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther 2019; 49:864&#x2013;872.</Citation></Reference><Reference><Citation>Lee KN, Lee OY, Chun HJ, et al. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World J Gastroenterol 2022; 28:6294&#x2013;6309.</Citation></Reference><Reference><Citation>Shin CM, Choi SC, Cho JW, et al. Comparison of tegoprazan and lansoprazole in patients with erosive esophagitis up to 4 weeks: a multi-center, randomized, double-blind, active-comparator phase 4 trial. Neurogastroenterol Motil 2025; 37:e14969.</Citation></Reference><Reference><Citation>Zhuang Q, Liao A, He Q, et al. The efficacy and safety of fexuprazan in treating erosive esophagitis: a phase III, randomized, double-blind, multicenter study. J Gastroenterol Hepatol 2024; 39:658&#x2013;666.</Citation></Reference><Reference><Citation>Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016; 43:240&#x2013;251.</Citation></Reference><Reference><Citation>Xiao Y, Zhang S, Dai N, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut 2020; 69:224&#x2013;230.</Citation></Reference><Reference><Citation>Gyawali CP, Yadlapati R, Fass R, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut 2024; 73:361&#x2013;371.</Citation></Reference><Reference><Citation>Seo S, Jung HK, Gyawali CP, et al. Treatment response with potassium-competitive acid blockers based on clinical phenotypes of gastroesophageal reflux disease: a systematic literature review and meta-analysis. J Neurogastroenterol Motil 2024; 30:259&#x2013;271.</Citation></Reference><Reference><Citation>Ashida K, Iwakiri K, Hiramatsu N, et al. Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol 2018; 24:1550&#x2013;1561.</Citation></Reference><Reference><Citation>Fass R, Chey WD, Zakko SF, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with nonerosive reflux disease. Aliment Pharmacol Ther 2009; 29:1261&#x2013;1272.</Citation></Reference><Reference><Citation>Weijenborg PW, Cremonini F, Smout AJ, et al. PPI therapy is equally effective in well defined nonerosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil 2012; 24:747&#x2013;757. e350.</Citation></Reference><Reference><Citation>Kinoshita Y, Sakurai Y, Shiino M, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp 2016; 81-82:1&#x2013;7.</Citation></Reference><Reference><Citation>Kinoshita Y, Sakurai Y, Takabayashi N, et al. Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study. Clin Transl Gastroenterol 2019; 10:e00101.</Citation></Reference><Reference><Citation>Kim SH, Cho KB, Chun HJ, et al. Randomised clinical trial: comparison of tegoprazan and placebo in nonerosive reflux disease. Aliment Pharmacol Ther 2021; 54:402&#x2013;411.</Citation></Reference><Reference><Citation>Laine L, Spechler S, Yadlapati R, et al. Vonoprazan is efficacious for treatment of heartburn in nonerosive reflux disease: a randomized trial. Clin Gastroenterol Hepatol 2024; 22:2211.e10&#x2013;2220.e10.</Citation></Reference><Reference><Citation>Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009; 58:295&#x2013;309.</Citation></Reference><Reference><Citation>Patel A, Laine L, Moayyedi P, Wu J. AGA clinical practice update on integrating potassium-competitive acid blockers into clinical practice: expert review. Gastroenterology 2024; 167:1228&#x2013;1238.</Citation></Reference><Reference><Citation>Kim JS, Seo SI, Kang SH, et al. Effects of tegoprazan versus esomeprazole on nighttime heartburn and sleep quality in gastroesophageal reflux disease: a multicenter double-blind randomized controlled trial. J Neurogastroenterol Motil 2023; 29:58&#x2013;64.</Citation></Reference><Reference><Citation>Oshima T, Arai E, Taki M, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther 2019; 49:140&#x2013;146.</Citation></Reference><Reference><Citation>Hoshikawa Y, Hoshino S, Kawami N, Iwakiri K, et al. Prevalence of behavioral disorders in patients with vonoprazan-refractory reflux symptoms. J Gastroenterol 2021; 56:117&#x2013;124.</Citation></Reference><Reference><Citation>Dickman R, Maradey-Romero C, Gingold-Belfer R, et al. Unmet needs in the treatment of gastroesophageal reflux disease. J Neurogastroenterol Motil 2015; 21:309&#x2013;319.</Citation></Reference><Reference><Citation>Khan Z, Alastal Y, Khan MA, et al. On-demand therapy with proton pump inhibitors for maintenance treatment of nonerosive reflux disease or mild erosive esophagitis: a systematic review and meta-analysis. Gastroenterol Res Pract 2018; 2018:6417526.</Citation></Reference><Reference><Citation>Kang SJ, Jung HK, Tae CH, et al. On-demand versus continuous maintenance treatment of gastroesophageal reflux disease with proton pump inhibitors: a systematic review and meta-analysis. J Neurogastroenterol Motil 2022; 28:5&#x2013;14.</Citation></Reference><Reference><Citation>Jung BW, Park CH, Eun CS. Preference for on-demand fexuprazan therapy in gastroesophageal reflux disease: a prospective cohort study. J Pers Med 2025; 15:19.</Citation></Reference><Reference><Citation>Fass R, Vaezi M, Sharma P, et al. Randomised clinical trial: efficacy and safety of on-demand vonoprazan versus placebo for nonerosive reflux disease. Aliment Pharmacol Ther 2023; 58:1016&#x2013;1027.</Citation></Reference><Reference><Citation>Kahrilas PJ. Editorial: on-demand vonoprazan for NERD-when should it be &#x2019;demanded&#x2019;? Aliment Pharmacol Ther 2023; 58:1230.</Citation></Reference><Reference><Citation>Yadlapati R, Gyawali CP, Pandolfino JE, et al. AGA Clinical Practice update on the personalized approach to the evaluation and management of GERD: expert review. Clin Gastroenterol Hepatol 2022; 20:984.e1&#x2013;994.e1.</Citation></Reference><Reference><Citation>Komanduri S, Kahrilas PJ, Krishnan K, et al. Recurrence of Barrett's esophagus is rare following endoscopic eradication therapy coupled with effective reflux control. Am J Gastroenterol 2017; 112:556&#x2013;566.</Citation></Reference><Reference><Citation>Spechler SJ, Sharma P, Traxler B, et al. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol 2006; 101:1964&#x2013;1971.</Citation></Reference><Reference><Citation>Chen Y, Sun C, Wu Y, et al. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.</Citation></Reference><Reference><Citation>Liu G, Wang P, Ran S, et al. Surgical treatment strategies for gastroesophageal reflux after laparoscopic sleeve gastrectomy. Front Endocrinol (Lausanne) 2024; 15:1463567.</Citation></Reference><Reference><Citation>Alcala-Gonzalez LG, Guillen-Del-Castillo A, Aguilar Cayuelas A, et al. Gastrointestinal dysmotility is associated with proton pump inhibitor refractory oesophagitis in patients with systemic sclerosis. Rheumatology (Oxford) 2025; 64:3074&#x2013;3079.</Citation></Reference><Reference><Citation>Nurczyk K, Farrell TM, Patti MG. Antireflux surgery for gastroesophageal reflux refractory to medical treatment after peroral endoscopic myotomy. J Laparoendosc Adv Surg Tech A 2020; 30:612&#x2013;614.</Citation></Reference><Reference><Citation>Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut 2013; 62:824&#x2013;832.</Citation></Reference><Reference><Citation>Gautam R, Lal M, Carroll MC, et al. Proton pump inhibitors modulate esophageal epithelial barrier function and crosstalk with eosinophils. bioRxiv 2024; doi: 10.1101/2024.08.22.609219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.08.22.609219</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishimura N, Ishihara S, Kinoshita Y. Sustained acid suppression by potassium-competitive acid blocker (P-CAB) may be an attractive treatment candidate for patients with eosinophilic esophagitis. Am J Gastroenterol 2016; 111:1203&#x2013;1204.</Citation></Reference><Reference><Citation>Kuzumoto T, Tanaka F, Sawada A, et al. Vonoprazan shows efficacy similar to that of proton pump inhibitors with respect to symptomatic, endoscopic, and histological responses in patients with eosinophilic esophagitis. Esophagus 2021; 18:372&#x2013;379.</Citation></Reference><Reference><Citation>Chey WD, Howden CW, Moss SF, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2024; 119:1730&#x2013;1753.</Citation></Reference><Reference><Citation>Li Y, Choi H, Leung K, et al. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2023; 8:553&#x2013;564.</Citation></Reference><Reference><Citation>Chey WD, Megraud F, Laine L, et al. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology 2022; 163:608&#x2013;619.</Citation></Reference><Reference><Citation>Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016; 65:1439&#x2013;1446.</Citation></Reference><Reference><Citation>Pharmaceuticals P. VOQUEZNA (vonoprazan) [prescribing information]. 2024.</Citation></Reference><Reference><Citation>Xie X, Ren K, Zhou Z, et al. The global, regional and national burden of peptic ulcer disease from 1990 to 2019: a population-based study. BMC Gastroenterol 2022; 22:58.</Citation></Reference><Reference><Citation>Vakil N. Peptic ulcer disease: a review. JAMA 2024; 332:1832&#x2013;1842.</Citation></Reference><Reference><Citation>Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol 2018; 3:231&#x2013;241.</Citation></Reference><Reference><Citation>Wang WX, Li RJ, Li XF. Efficacy and safety of potassium-competitive acid blockers vs proton pump inhibitors for peptic ulcer disease or postprocedural artificial ulcers: a systematic review and meta-analysis. Clin Transl Gastroenterol 2024; 15:e1.</Citation></Reference><Reference><Citation>Dong Y, Xu H, Zhang Z, et al. Comparative efficiency and safety of potassium competitive acid blockers versus Lansoprazole in peptic ulcer: a systematic review and meta-analysis. Front Pharmacol 2023; 14:1304552.</Citation></Reference><Reference><Citation>Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, noninferiority randomised controlled trials. Aliment Pharmacol Ther 2017; 45:240&#x2013;252.</Citation></Reference><Reference><Citation>Ouyang M, Zou S, Cheng Q, et al. Comparative efficacy and safety of potassium-competitive acid blockers vs. proton pump inhibitors for peptic ulcer with or without Helicobacter pylori infection: a systematic review and network meta-analysis. Pharmaceuticals (Basel) 2024; 17:698.</Citation></Reference><Reference><Citation>Hamada K, Uedo N, Tonai Y, et al. Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study. J Gastroenterol 2019; 54:122&#x2013;130.</Citation></Reference><Reference><Citation>Hirai A, Takeuchi T, Takahashi Y, et al. Comparison of the effects of vonoprazan and lansoprazole for treating endoscopic submucosal dissection-induced artificial ulcers. Dig Dis Sci 2018; 63:974&#x2013;981.</Citation></Reference><Reference><Citation>Ichida T, Ueyama S, Eto T, et al. Randomized controlled trial comparing the effects of vonoprazan plus rebamipide and esomeprazole plus rebamipide on gastric ulcer healing induced by endoscopic submucosal dissection. Intern Med 2019; 58:159&#x2013;166.</Citation></Reference><Reference><Citation>Ishii Y, Yamada H, Sato T, et al. Effects of vonoprazan compared with esomeprazole on the healing of artificial postendoscopic submucosal dissection ulcers: a prospective, multicenter, two-arm, randomized controlled trial. Gastroenterol Res Pract 2018; 2018:1615092.</Citation></Reference><Reference><Citation>Jaruvongvanich V, Poonsombudlert K, Ungprasert P. Vonoprazan versus proton-pump inhibitors for gastric endoscopic submucosal dissection-induced ulcers: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2018; 30:1416&#x2013;1421.</Citation></Reference><Reference><Citation>Kagawa T, Iwamuro M, Ishikawa S, et al. Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. Aliment Pharmacol Ther 2016; 44:583&#x2013;591.</Citation></Reference><Reference><Citation>Liu C, Feng BC, Zhang Y, et al. The efficacy of vonoprazan for management of postendoscopic submucosal dissection ulcers compared with proton pump inhibitors: a meta-analysis. J Dig Dis 2019; 20:503&#x2013;511.</Citation></Reference><Reference><Citation>Martin, Zhou Y, Meng CX, et al. Vonoprazan vs proton pump inhibitors in treating postendoscopic submucosal dissection ulcers and preventing bleeding: a meta-analysis of randomized controlled trials and observational studies. Medicine (Baltimore) 2020; 99:e19357.</Citation></Reference><Reference><Citation>Tsuchiya I, Kato Y, Tanida E, et al. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: prospective randomized controlled trial. Dig Endosc 2017; 29:576&#x2013;583.</Citation></Reference><Reference><Citation>Tsujita K, Deguchi H, Uda A, et al. Upper gastrointestinal bleeding in Japanese patients with ischemic heart disease receiving vonoprazan or a proton pump inhibitor with multiple antithrombotic agents: a nationwide database study. J Cardiol 2020; 76:51&#x2013;57.</Citation></Reference><Reference><Citation>Yamamoto S, Takayama H, Shimodate Y, et al. Effect of vonoprazan on delayed bleeding after endoscopic submucosal dissection for gastric neoplasia among antithrombotic drug users: a single-center, single-arm prospective observational case control study. Acta Med Okayama 2020; 74:245&#x2013;250.</Citation></Reference><Reference><Citation>Yoshii S, Yamada T, Yamaguchi S, et al. Efficacy of vonoprazan for the prevention of bleeding after gastric endoscopic submucosal dissection with continuous use of antiplatelet agents. Endosc Int Open 2020; 8:E481&#x2013;E487.</Citation></Reference><Reference><Citation>Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 2018; 67:1033&#x2013;1041.</Citation></Reference><Reference><Citation>Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled noninferiority and single-blind extension study. Gut 2018; 67:1042&#x2013;1051.</Citation></Reference><Reference><Citation>Li T, Qiao H, Yue P, et al. Embryo-fetal toxicity assessment of vonoprazan in rats and rabbits. J Appl Toxicol 2018; 38:987&#x2013;995.</Citation></Reference><Reference><Citation>Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis. J Gastroenterol Hepatol 2022; 37:2217&#x2013;2228.</Citation></Reference><Reference><Citation>Zhuang Q, Chen S, Zhou X, et al. Comparative efficacy of P-CAB vs proton pump inhibitors for grade C/D esophagitis: a systematic review and network meta-analysis.</Citation></Reference><Reference><Citation>Uemura N, Kinoshita Y, Haruma K, et al. Vonoprazan as a long-term maintenance treatment for erosive esophagitis: VISION, a 5-year, randomized, open-label study. Clin Gastroenterol Hepatol 2025; 23:748.e5&#x2013;757.e5.</Citation></Reference><Reference><Citation>Arai J, Miyawaki A, Aoki T, et al. Association between vonoprazan and the risk of gastric cancer after Helicobacter pylori eradication. Clin Gastroenterol Hepatol 2024; 22:1217.e6&#x2013;1225.e6.</Citation></Reference><Reference><Citation>Tan MC, Graham DY. Proton pump inhibitor therapy after Helicobacter pylori eradication may increase the risk of gastric cancer. BMJ Evid Based Med 2018; 23:111&#x2013;112.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>